Gapping up
In reaction to earnings/guidance:
- ETH +12.6%, NWHM +4.9% (reports prelim Q3 results), NVMI +3.8% (Q3 guidance), CMBM +3.4% (Q3 guidance), BLK +3.1%, FRC +3%, EDU +2.1%, JPM +1%
Other news:
- IVA +11.3% (received FDA Breakthrough Therapy designation for lanifibranor in NASH)
- DIS +5.4% (announced strategic reorganization of media and entertainment businesses to accelerate DTC strategy)
- EXC +5.1% (Bloomberg report suggests co is evaluating potential spin of non-utility assets)
- AXGT +4.6% (received Rare Pediatric Disease Designation from the FDA for AXO-AAV-GM2)
- LEU +3.6% (Centrus Energy and Terrestrial Energy USA partner on fuel supply for IMSR Generation IV nuclear plants)
- SRNE +3.2% (announced exclusive license agreement with Personalized Stem Cells for rights to mesenchymal stem cell program)
- TWST +3% (Twist Bioscience and Neogene Therapeutics announced a broad strategic partnership)
- FLR +2.5% (awarded a three-year maintenance contract by NAM (Nederlandse Aardolie Maatschappij), a joint venture between Shell and Esso, in the Netherlands
- WSM +1.6% (increased dividend, resumed share repurchases, and paid down $500 mln revolver)
Analyst comments:
- FL +3.5% (upgraded to Buy from Underperform at BofA Securities)
- GTES +2.8% (upgraded to Buy from Neutral at UBS)
- MU +2.4% (upgraded to Buy from Hold at Deutsche Bank)
- CSX +2% (upgraded to Outperform from Mkt Perform at Bernstein)
- XEC +1.9% (upgraded to Buy from Hold at Truist)
- PK +1.7% (upgraded to Outperform from Market Perform at BMO Capital Markets;)
- ATUS +1.5% (upgraded to Overweight from Neutral at Atlantic Equities)
- NTAP +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CTSH +1.4% (upgraded to Positive from Neutral at Susquehanna)
- CUBE +1.2% (upgraded to Buy from Hold at Jefferies)
- MAR +0.8% (upgraded to Market Perform from Underperform at BMO Capital Markets)